Targets › TLR7
21 programs from 20 companies in 39 trials: 16 Phase 2, 15 Phase 1, 6 Phase 3, 2 Phase 4; Oncology, Immunology, Infectious disease; next expected readout Dec 2026.
Endosomal receptor that plays a key role in innate and adaptive immunity. Controls host immune response against pathogens through recognition of uridine-containing single strand RNAs (ssRNAs) of viral origin or guanosine analogs. (UniProt, Q9NYK1)
Open in Phaseline: the race on TLR7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Taiwan University Hospital | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 4 | Graves Ophthalmopathy; Steatohepatitis, Nonalcoholic | Jun 2027 |
| University of Oxford | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 3 | Pneumonia; COVID-19 | Jan 2027 |
| NYU Langone Health | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 3 | Systemic Lupus Erythematosus; Rheumatic Disease | Jan 2028 |
| Merck KGaA | Enpatoran Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist | TLR8, TLR7 | Phase 3 | Systemic Lupus Erythematosus (SLE); Systematic Lupus Erythematosus | May 2029 |
| Eikon Therapeutics | EIK1001 Toll-like receptor 7/8 (TLR 7/8) agonist | TLR7, TLR8 | Phase 2 | NSCLC; Advanced Melanoma; Non Small Cell Lung Cancer (Squamous or Non Squamous) | Dec 2026 |
| Abramson Cancer Center at Penn Medicine | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 2 | Breast Cancer Stage IIB; Breast Cancer | Jan 2027 |
| Medical University of South Carolina | Hydroxychloroquine Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 2 | Ovarian Cancer; Prostate Cancer Recurrent | May 2027 |
| Primmune Therapeutics | PRTX007 TLR7 agonist prodrug (prodrug of PRX034) | TLR7 | Phase 2 | Melanoma Stage III | Dec 2027 |
| M.D. Anderson Cancer Center | SAR445877 TLR7/8 agonist | TLR7, TLR8 | Phase 2 | Non-Small Cell Lung Cancer; Phase 1 | Feb 2028 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | VIR-2218 TLR7 agonist | TLR7 | Phase 2 | Chronic Hepatitis B | Feb 2028 |
| Merck KGaA | Enpatoran (M5049) Toll-like receptor 8 antagonist; Toll-like receptor 7 antagonist | TLR8, TLR7 | Phase 2 | Systemic Lupus Erythematosus | Aug 2028 |
| Beeline Medicines | Afimetoran (BLN-256) Toll-like receptor 8 inhibitor; Toll-like receptor 7 inhibitor | TLR8, TLR7 | Phase 2 | Systemic Lupus Erythematosus; Cutaneous Lupus Erythematosus (CLE) | Apr 2029 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 3M-052-AF Toll-like receptor 7/8 agonist | TLR7, TLR8 | Phase 1 | Hiv; HIV | Dec 2026 |
| OX2 Therapeutics | Imiquimod Toll-like receptor 7 agonist | TLR7 | Phase 1 | Diffuse Midline Glioma, H3 K27M-Mutant; HSIL, High-Grade Squamous Intraepithelial Lesions; Basal Cell Carcinoma; Cervical Carcinoma … | Jan 2027 |
| Bolt Biotherapeutics | BDC-4182 Anti-CLDN18.2 monoclonal antibody conjugated to TLR7/8 dual agonist | CLDN18, TLR7, TLR8 | Phase 1 | Gastric Cancer Adenocarcinoma Metastatic | May 2027 |
| West Virginia University | Hydroxychloroquine sulfate Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 1 | Adenocarcinoma of the Pancreas | Jun 2027 |
| Ascendis Pharma Oncology Division | TransCon TLR7/8 Agonist TLR7/8 agonist with extended half-life via TransCon technology | TLR7, TLR8 | Phase 1 | Advanced Solid Tumor | Aug 2027 |
| HighField Biopharmaceuticals | HF50 Liposome-encapsulated bifunctional therapeutic; HER2-redirected T-cell engager with TLR7/8 | ERBB2, TLR7, TLR8 | Phase 1 | Advanced Solid Tumors | Jun 2028 |
| United Immunity | UI-102 TLR7/8 agonist encapsulated in Cholesteryl Pullulan Nanoparticle | TLR7, TLR8 | Phase 1 | Advanced Cancer | Mar 2030 |
| Xingchen Peng | Hydroxychloroquine Sulfate Toll-like receptor 7 antagonist; Toll-like receptor 9 antagonist | TLR7, TLR9 | Phase 1 | Radiation-induced Oral Mucositis | – |
| Inimmune | INI-4001 TLR7/8 agonist | TLR7, TLR8 | Phase 1 | Advanced Solid Tumor | – |
Systemic Lupus Erythematosus (3) Breast Cancer (2) Diffuse Midline Glioma, H3 K27M-Mutant (2) Advanced Solid Tumor (2) Adenocarcinoma of the Pancreas (1) Breast Cancer Stage IIB (1) Graves Ophthalmopathy (1) Steatohepatitis, Nonalcoholic (1) Systemic Lupus Erythematosus (SLE) (1) Systematic Lupus Erythematosus (1) NSCLC (1) Advanced Melanoma (1)
small molecule (11), mixed (9), protein or peptide (1)
Merck KGaA (2) West Virginia University (1) Abramson Cancer Center at Penn Medicine (1) National Taiwan University Hospital (1) Eikon Therapeutics (1) United Immunity (1) Beeline Medicines (1) National Institute of Allergy and Infectious Diseases (NIAID) (1) OX2 Therapeutics (1) Medical University of South Carolina (1) NYU Langone Health (1) M.D. Anderson Cancer Center (1) Primmune Therapeutics (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) HighField Biopharmaceuticals (1) Ascendis Pharma Oncology Division (1) Xingchen Peng (1) University of Oxford (1) Bolt Biotherapeutics (1) Inimmune (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.